News | January 21, 2011

FDA Panel Recommends Conditional Approval for PET Agent

January 21, 2011 — The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee decided that it could not recommend approval of Amyvid (florbetapir) at this time based on the currently available data (13-3); but, voted unanimously (16-0) to recommend approval of Amyvid conditional on a reader training program that demonstrates reader accuracy and consistency through a re-read of previously acquired scans. The committee said efficacy was established and there were no significant safety concerns raised.

Amyvid is an imaging tool indicated for positron emission tomography (PET) imaging of beta-amyloid plaque in the brain. It is being investigated for the potential use in ruling out Alzheimer's disease. In addition to the pivotal phase III "Image-to-Autopsy" study, other clinical studies are also being conducted in the European Union., North and South America, Australia and Asia. The committee stated that a negative scan would be clinically useful in indicating that Alzheimer's pathology is unlikely to be the cause of a patient's cognitive decline.

Lilly acquired Avid Radiopharmaceuticals Inc. in December 2010. Amyvid is Avid's lead candidate and was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the United States. Amyvid was recently assigned priority review designation by the FDA.

The FDA will consider the panel's recommendation in its review of Amyvid. The FDA takes the advice of its advisory committees into consideration when reviewing investigational drugs, but is not bound by their recommendations.

For more information: www.lilly.com

Related Content

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
News | Lung Cancer | July 16, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
High-Strength MRI May Release Mercury from Amalgam Dental Fillings
News | Magnetic Resonance Imaging (MRI) | July 05, 2018
Exposure to ultra-high-strength magnetic resonance imaging (MRI) may release toxic mercury from amalgam fillings in...
Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning.

Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning. (Images courtesy of Metrasens)

Feature | Magnetic Resonance Imaging (MRI) | July 03, 2018 | By Tobias Gilk
Nearly every job in the country is subject to certain health and safety regulations. Construction workers must wear...
Carestream DRX-Revolution Nano Mobile X-ray System

The Carestream DRX-Revolution Nano Mobile X-ray System.

Feature | Digital Radiography (DR) | July 03, 2018 | By Melinda Taschetta-Millane
The mobile digital radiography (DR) segment is the largest segment by product type in the global digital mobile DR...
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
Overlay Init